ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

Peer Review changes Urged By NIH Team Include Appeals

April 8, 1977

Cancer Control Awards $1 .5 Million Grant For 3-Year Study By College Of Radiology

April 26, 1974

Brandt Tells NIK There May Be No Exceptions To DRG Regulations, Maybe a Few At Comprehensive Centers

June 24, 1983

ASCO To Begin Large Study On Quality Of Cancer Care.

January 28, 2000

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

Call to Shift Two-Thirds Of Funds a “Rubber Number,” Bailar Says

June 6, 1997